Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
9 p, 929.7 KB Reimbursement status and recommendations related to orphan drugs in European countries / Stawowczyk, E. (University of Bielsko-Biala. Faculty of Health Sciences) ; Malinowski, K. P. (Jagiellonian University Medical College) ; Kawalec, P. (Jagiellonian University Medical College) ; Bobiński, R. (Jagiellonian University Medical College) ; Siwiec, J. (Jagiellonian University Medical College) ; Panteli, D. (European Observatory on Health Systems and Policies) ; Eckhardt, H. (European Observatory on Health Systems and Policies) ; Simoens, Steven (KU Leuven. Department of Pharmaceutical and Pharmacological Sciences) ; Agustí Escasany, M. Antònia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Dooms, M. (University Hospitals Leuven (Bèlgica)) ; Pilc, A. (Polish Academy of Sciences. Institute of Pharmacology)
Objective: To review the reimbursement recommendations issued by selected European health technology assessment agencies for orphan drugs and the reimbursement status of these drugs; to assess the relationship between the type of recommendation and reimbursement status. [...]
2019 - 10.3389/fphar.2019.01279
Frontiers in Pharmacology, Vol. 10 (2019), p. 1279  
2.
13 p, 1.0 MB Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation / Vella Bonanno, Patricia (Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde) ; Ermisch, Michael (Pharmaceutical Department, National Association of Statutory Health Insurance Funds) ; Godman, Brian (Karolinska Institutet (Estocolm, Suècia). Division of Clinical Pharmacology) ; Martin, Antony P. (Health Economics Centre, University of Liverpool Management School) ; Van Den Bergh, Jesper (Department of Health) ; Bezmelnitsyna, Liudmila (National Research Institution for Public Health) ; Bucsics, Anna (Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)) ; Arickx, Francis (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Bybau, Alexander (Zilveren Kruis Achmea) ; Bochenek, Tomasz (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College) ; van de Casteele, Marc (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ; Eriksson, Irene (Karolinska Institutet (Estocolm, Suècia). Department of Medicine Solna) ; Fürst, Jurij (Medicinal Products Department, Health Insurance Institute of Slovenia) ; Gad, Mohamed (Global Health and Development Group, Imperial College) ; Greičiūtė-Kuprijanov, Ieva (Department of Pharmacy, Ministry of Health of the Republic of Lithuania) ; van der Graaff, Martin (National Health Care Institute (ZIN)) ; Gulbinovič, Jolanta (State Medicines Control Agency) ; Jones, Jan (Scottish Medicines Consortium) ; Joppi, Roberta (Clinical Research and Drug Assessment Unit) ; Kalaba, Marija (Pediatric Cardiology, Primary Healthcare Centre "Zemun") ; Laius, Ott (Department of Post-authorisation Safety, State Agency of Medicines) ; Langner, Irene (Wissenschaftliches Institut der AOK) ; Mardare, Ileana (Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest) ; Markovic-Pekovic, Vanda (Department of Social Pharmacy, Medical Faculty, University of Banja Luka) ; Magnusson, Einar (Department of Health Services, Ministry of Health) ; Melien, Oyvind (Norwegian Directorate for Health) ; Meshkov, Dmitry O. (Department of Health) ; Petrova, Guenka I. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia) ; Selke, Gisbert (Wissenschaftliches Institut der AOK) ; Sermet, Catherine (Institut de Recherche et Documentation en Economie de la Santé (IRDES)) ; Simoens, Steven (KU Leuven Department of Pharmaceutical and Pharmacological Sciences) ; Schuurman, Ad (National Health Care Institute (ZIN)) ; Ramos, Ricardo (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Rodrigues, Jorge (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Zara, Corinne (Servei Català de la Salut) ; Zebedin-Brandl, Eva (Main Association of Austrian Social Insurance Institutions. Department of Pharmaceutical Affairs) ; Haycox, Alan (Health Economics Centre, University of Liverpool Management School) ; Universitat Autònoma de Barcelona
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. [...]
2017 - 10.3389/fphar.2017.00497
Frontiers in Pharmacology, Vol. 8 (august 2017)  

Vea también: autores con nombres similares
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.